{"entity":{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","aka":["Xynomic Pharmaceuticals Holdings","Xynomic Pharma"],"tldr":"Xynomic Pharmaceuticals is a Chinese-American biotech that licensed the histone deacetylase inhibitor abexinostat from Pharmacyclics and is testing it with pazopanib in kidney cancer and alone in lymphoma.","summary":"Xynomic Pharmaceuticals is an oncology company with operations in Zhongshan, Guangdong and the San Francisco Bay Area. Its lead asset is abexinostat, a pan-histone deacetylase inhibitor in-licensed from Pharmacyclics (now part of AbbVie), which it has taken into a phase 3 trial with pazopanib in renal cell carcinoma and into follicular lymphoma studies in China. It also holds rights to the pan-RAF inhibitor XP-102 and other clinical-stage assets.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.xynomicpharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["abexinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Zhongshan","country":"CN","companyType":"biotech","website":"https://www.xynomicpharma.com/","investors":[],"funding":[]},"route":"/companies/xynomic-pharmaceuticals/","neighbours":{"drug":[{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/"}],"trial":[{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","route":"/trials/nct04024696/"},{"id":"nct03934567","kind":"trial","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03934567/"},{"id":"renaviv","kind":"trial","name":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","route":"/trials/renaviv/"},{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/"},{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct03936153/"},{"id":"nct05275374","kind":"trial","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","route":"/trials/nct05275374/"}]}}